Replies to post #796664 on NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

$NWBO 4 Gen 💰
She is a writer Attended numerous Shareholder Meetings & has interacted with MAESTRO

MAESTRO 1st job @
Latham Watkins
specializing hostile takeovers

'97 left Enron EARLY

Maverick_1, I'm glad to hear you say this https://t.co/IgoLm6ipNZ via @Investors_Hub

— maverick_1 (@maveric92283613) November 7, 2025

DIFFERENT STROKES for DIFFERENT FOLKS

[evanstony]

Maverick_1, I'm glad to hear you say this:


A BUYOUT does NOT even pass my SMELL TEST!

After getting past the immature condescending judgement of others and then the self glorifications that permeates all of Mavs posts.... the reason why there is a reason to SMELL a BO is what NWBO represents as an opportunity.

It is fair to say that LP has put in place and messaged the "franchise" future for the company.

IMO a BO may come because of this along with the significant IP combined with Flaskworks. LP may want to go it alone but when the BO offer is made all of the shareholders will decide.

Is this Paradigm shift a precious rare opportunity?? IMO it is and it will motivate more than one suitor.

The combinations for many indications and the manufacturing look like a war chest for winning massive income.

So this is an opinion based on opportunity and the greed of our competitors. Will it happen quickly? Probably not. My guess is within 3-4 months after approval.

[Doc logic]

beartrap12,

Long ago I looked into the bylaws which are referenced in the filings but not in detail. Between what Linda has done to create board control and the bylaws there is nearly no way to gain control outside of board agreement. Having Advent and Cognate separate created another layer of protection through public vs private ownership. This gave investors concerned about the possibility of a hostile takeover attempt but without understanding of the control afforded elsewhere a more visible layer of protection. Best wishes.